Brian Frenzel has dedicated his career in the life sciences industry to improving outcomes for patients suffering from debilitating and potentially life-threatening illnesses. Early in his career, he focused on infectious diseases such as AIDS and hepatitis and women’s health conditions such as preterm labor and dysfunctional uterine bleeding. More recently, Brian Frenzel has devoted his professional efforts toward cancer at Tosk, Inc. and neurodegenerative diseases at SanBio Ltd.
Tosk aims to improve patient outcomes for patients living with cancer. The company is involved in the development of drugs that improve the efficacy of existing cancer treatments and in discovering new drugs that disrupt the activity of cancer genes. When it comes to improving patient care, Tosk seeks to reduce or eliminate the adverse side effects of cancer treatments such as chemotherapy and radiation. These side effects can limit the dosing of cancer therapy and can be further debilitating to patients already suffering from disease. Tosk is currently developing drugs to ameliorate side effects such as mucositis. cardiomyopathy and congestive heart failure, kidney toxicity, and peripheral neuropathy.
0 Comments
|
AuthorAt Genelabs Technologies in the 1980’s, Brian Frenzel served on the front lines in the war on HIV/AIDS and championed projects to identify and diagnose new hepatitis viruses. Archives
June 2020
Categories
All
|